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OBJECTIVES: To estimate treatment costs attributable to over-
weight or obesity in diabetic patients. METHODS: Data from
23,825 adults in the 2004 Medical Expenditure Panel Survey
(MEPS), a nationally representative sample of the U.S. non-insti-
tutionalized population, were examined for this cross-sectional
analysis. Diabetic patients were identiﬁed if they reported having
diabetes in the medical conditions ﬁle of MEPS. Based on their
BMI, patients were further classiﬁed as normal (body mass index
(BMI 18.5 to <25), overweight (BMI 25 to <30), or obese (BMI
≥ 30). Treatment costs associated with diabetes mellitus included
costs for treating kidney and heart disease, stroke, eye, skin, and
foot complications, and neuropathy. The costs for overweight or
obese patients were predicted from estimated parameters in
patients with normal weight using a generalized linear model
with log link function, with adjustment for patients’ demo-
graphic characteristics, BMI, services used, and co-morbidities.
Attributable costs were estimated by the difference between pre-
dicted costs and observed costs. All costs were converted to 2005
U.S. dollars using appropriate price indices. Data were analyzed
using SAS and SUDAAN statistical software to adjust for the
complex sample design. RESULTS: The age-adjusted prevalence
of diabetes in the U.S. population was 6.26% (15.3 million
people). More than 80% of diabetic patients were overweight
(30.4%) or obese (51.4%). Among obese patients, the medical
costs associated with diabetes were higher in women ($6263)
than men ($4505), as well as in white ($6209) than black
($4819) or Hispanic ($2421) patients. Overall, compared to
patients with normal weight, predicted costs attributable to over-
weight were $709 (95% CI:$237–$1181) and obesity, $2301
(95% CI:$748–$3854). CONCLUSION: Overweight and
obesity were prevalent in diabetic patients that signiﬁcantly
increased economic burden. Patient education to emphasize the
importance of weight control is strongly recommended to reduce
treatment costs attributable to diabetic complications.
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EMERGENCY ROOM CARE FOR DIABETES MELLITUS IN THE
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OBJECTIVES: The objectives of this study were (1) To provide
a population-based estimate of the cost of emergency room care
for the US population with diabetes in 2006 dollars and; (2) To
examine if there are any differences in ER costs for the study
population by age, gender, race, ethnicity, marital status, insur-
ance status, educational level, family income, census region,
locality, body mass index, and comorbidities/complications
METHODS: This was a cross-sectional retrospective study of the
cost of emergency room care for individuals with diabetes. The
data source for the study was the 2003 MEPS Household Com-
ponent Full Year Consolidated File (MEPS HC-079, 2003).
People reporting diabetes in the MEPS data ﬁle were identiﬁed
by the ICD9-CM code 250 (diabetes) and the relevant ICD9-CM
codes were used to further identify those individuals reporting
both diabetes and any of the associated comorbidities/complica-
tions after merging the data by the person identiﬁcation number
DUPERSID. The total cost of ER care for the study population
was computed by summing the facility and provider costs for the
year and then adjusted to 2006 dollars. Differences in the mean
ER cost for diabetes by each of the demographic and clinical
variables were tested for signiﬁcance using two sample t-tests.
All computations and analyses incorporated the MEPS sampling
weights to obtain estimates for the noninstitutionalized US civil-
ian population with diabetes in 2003. RESULTS: The total cost
of ER care for diabetes in 2003 was $3.1 billion adjusted to $3.4
billion in 2006 dollars. The difference in the mean ER cost was
signiﬁcant only by gender and educational level. CONCLU-
SION: ER care for diabetes cost $3.4 billion in 2006. Appro-
priate educational interventions might be needed for people with
diabetes so they can better cooperate with their providers in their
disease management so as to reduce ER use and costs.
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OBJECTIVES: The objective of the present study was to esti-
mate annual costs of care incurred by Swedish patients with type
2 diabetes between 2000 and 2004 and to determine the drivers
of costs using data from the RECAP-DM study, which included
medical records on 11,856 patients with type 2 diabetes 
retrospectively identiﬁed in computerised registers at 26 primary
care centres in Uppsala county (°Ö300,000 inhabitants).
METHODS: Costs of outpatient care, drugs and devices were
estimated by assigning unit costs from published sources to 
care-giver contacts and prescriptions recorded in computerised
primary care records. Costs of inpatient care were estimated by
classifying hospitalisations of study patients into diagnosis-
related groups (DRGs) according to the Nord-DRG classiﬁcation
system and assigning average costs per DRG. Costs of dialysis
were estimated using data from the Swedish Register for Active
Care of Renal Failure. Drivers of costs were analysed through
multiple regression analysis. RESULTS: The average annual cost
of care over the studied years was $2658 per patient (n = 7269
on average). Costs of inpatient care accounted for an average
59% of total costs. Results of the regression analysis indicated
that the main driver of costs was the presence of complications.
Undergoing treatment for renal failure in a given year was asso-
ciated with a $70,682 increase in total costs of care during the
year. Experiencing a major cardiovascular event (acute MI,
stroke, PCI or CABG) in a given year was associated with a
$15,094 increase in total costs of care during the year. CON-
CLUSION: Diabetes continues to impose a heavy economic
burden on society. Cost estimates from this population-based
sample of Swedish type 2 diabetics may serve as reference values
for a Swedish setting and provide additional information on the
composition of costs.
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of insulin glargine in the UK for people
with Type 2 diabetes mellitus (T2DM) using observational data
in patients continuing on NPH versus those switching from NPH
to insulin glargine. METHODS: A discrete event simulation was
